Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f7e040c8333d42af9a814346b023d546 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|